Literature DB >> 19099279

A novel peptide motif binding to and blocking the intracellular activity of the human papillomavirus E6 oncoprotein.

Susanne Dymalla1, Martin Scheffner, Elvira Weber, Peter Sehr, Claudia Lohrey, Felix Hoppe-Seyler, Karin Hoppe-Seyler.   

Abstract

Specific types of human papillomaviruses (HPVs) cause cervical cancer. The viral E6 oncogene is a critical factor for maintaining the malignant phenotype of HPV-positive tumour cells. By yeast two-hybrid screening of a randomised peptide expression library, we isolated linear short peptides, which specifically bind to the HPV16 E6 oncoprotein. Sequence alignments and mutational analyses of the peptides identified a hitherto undiscovered E6-binding motif. Intracellular expression of a peptide containing the novel E6-binding motif resulted in inhibition of colony formation capacity, specifically of HPV16-positive cancer cells. A solubility-optimised variant of the peptide was created, which binds to HPV16 E6 with high affinity. Its intracellular expression efficiently induced apoptosis in HPV16-positive cancer cells. This was linked to restoration of intracellular p53 activities. Thus, this newly identified E6-binding motif could form a novel basis for the development of rational strategies for the treatment of HPV16-positive preneoplastic and neoplastic lesions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19099279     DOI: 10.1007/s00109-008-0432-1

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  36 in total

Review 1.  The design, synthesis and application of stereochemical and directional peptide isomers: a critical review.

Authors:  P M Fischer
Journal:  Curr Protein Pept Sci       Date:  2003-10       Impact factor: 3.272

2.  A transcriptionally active DNA-binding site for human p53 protein complexes.

Authors:  W D Funk; D T Pak; R H Karas; W E Wright; J W Shay
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

3.  A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F.

Authors:  K Helin; J A Lees; M Vidal; N Dyson; E Harlow; A Fattaey
Journal:  Cell       Date:  1992-07-24       Impact factor: 41.582

4.  Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis.

Authors:  Yves Nominé; Murielle Masson; Sebastian Charbonnier; Katia Zanier; Tutik Ristriani; François Deryckère; Annie-Paule Sibler; Dominique Desplancq; Robert Andrew Atkinson; Etienne Weiss; Georges Orfanoudakis; Bruno Kieffer; Gilles Travé
Journal:  Mol Cell       Date:  2006-03-03       Impact factor: 17.970

5.  Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein.

Authors:  K Butz; C Denk; A Ullmann; M Scheffner; F Hoppe-Seyler
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

6.  Identification of an alpha helical motif sufficient for association with papillomavirus E6.

Authors:  J J Chen; Y Hong; E Rustamzadeh; J D Baleja; E J Androphy
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

7.  Cloning of human ubiquitin-conjugating enzymes UbcH6 and UbcH7 (E2-F1) and characterization of their interaction with E6-AP and RSP5.

Authors:  U Nuber; S Schwarz; P Kaiser; R Schneider; M Scheffner
Journal:  J Biol Chem       Date:  1996-02-02       Impact factor: 5.157

8.  Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53.

Authors:  F Hoppe-Seyler; K Butz
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

9.  siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells.

Authors:  Karin Butz; Tutik Ristriani; Arnd Hengstermann; Claudia Denk; Martin Scheffner; Felix Hoppe-Seyler
Journal:  Oncogene       Date:  2003-09-04       Impact factor: 9.867

10.  Inhibition of E6-induced degradation of its cellular substrates by novel blocking peptides.

Authors:  Helena Sterlinko Grm; Malte Weber; Rob Elston; Pauline McIntosh; Heather Griffin; Lawrence Banks; John Doorbar
Journal:  J Mol Biol       Date:  2004-01-23       Impact factor: 5.469

View more
  13 in total

1.  The novel fusion protein sTRAIL-TMTP1 exhibits a targeted inhibition of primary tumors and metastases.

Authors:  Ronghua Liu; Xiangyi Ma; Hongyan Wang; Yandong Xi; Min Qian; Wanhua Yang; Danfeng Luo; Liangsheng Fan; Xi Xia; Jianfeng Zhou; Li Meng; Shixuan Wang; Ding Ma; Ling Xi
Journal:  J Mol Med (Berl)       Date:  2013-10-26       Impact factor: 4.599

2.  Isolation of peptides blocking the function of anti-apoptotic Livin protein.

Authors:  Irena Crnković-Mertens; Julia Bulkescher; Christina Mensger; Felix Hoppe-Seyler; Karin Hoppe-Seyler
Journal:  Cell Mol Life Sci       Date:  2010-02-23       Impact factor: 9.261

3.  Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.

Authors:  Changyou Li; Daniel E Johnson
Journal:  Cell Cycle       Date:  2013-02-19       Impact factor: 4.534

Review 4.  Therapy of human papillomavirus-related disease.

Authors:  Peter L Stern; Sjoerd H van der Burg; Ian N Hampson; Thomas R Broker; Alison Fiander; Charles J Lacey; Henry C Kitchener; Mark H Einstein
Journal:  Vaccine       Date:  2012-11-20       Impact factor: 3.641

5.  Novel Affibody Molecules Targeting the HPV16 E6 Oncoprotein Inhibited the Proliferation of Cervical Cancer Cells.

Authors:  Jinshun Zhu; Saidu Kamara; Qi Wang; Yanru Guo; Qingfeng Li; Linlin Wang; Jingjing Chen; Qianqian Du; Wangqi Du; Shao Chen; Shanli Zhu; Jun Chen; Maoping Chu; Lifang Zhang
Journal:  Front Cell Dev Biol       Date:  2021-05-24

6.  Small molecule inhibitors of human papillomavirus protein - protein interactions.

Authors:  C M D'Abramo; J Archambault
Journal:  Open Virol J       Date:  2011-07-04

7.  The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6.

Authors:  Katia Zanier; Christina Stutz; Susanne Kintscher; Eileen Reinz; Peter Sehr; Julia Bulkescher; Karin Hoppe-Seyler; Gilles Travé; Felix Hoppe-Seyler
Journal:  PLoS One       Date:  2014-11-10       Impact factor: 3.240

8.  Selective antitumor activity of roscovitine in head and neck cancer.

Authors:  Cyril Gary; Michael Hajek; Asel Biktasova; Gary Bellinger; Wendell G Yarbrough; Natalia Issaeva
Journal:  Oncotarget       Date:  2016-06-21

Review 9.  PPI Modulators of E6 as Potential Targeted Therapeutics for Cervical Cancer: Progress and Challenges in Targeting E6.

Authors:  Lennox Chitsike; Penelope J Duerksen-Hughes
Journal:  Molecules       Date:  2021-05-18       Impact factor: 4.411

10.  Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.

Authors:  Christina Stutz; Eileen Reinz; Anja Honegger; Julia Bulkescher; Johannes Schweizer; Katia Zanier; Gilles Travé; Claudia Lohrey; Karin Hoppe-Seyler; Felix Hoppe-Seyler
Journal:  PLoS One       Date:  2015-07-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.